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Summary
Background Although the association between psychotic illness and cigarette smoking is well known, the reasons are 
unclear why people with psychosis are more likely to smoke than are the general population. We aimed to test several 
hypotheses. First, that daily tobacco use is associated with an increased risk of psychotic illness in both case-control 
and prospective studies. Second, that smoking is associated with an earlier age at onset of psychotic illness. Finally, 
that an earlier age at initiation of smoking is associated with an increased risk of psychosis. We also aimed to derive 
an estimate of the prevalence of smoking in patients presenting with their ﬁ rst episode of psychosis.
Methods We searched Embase, Medline, an d PsycINFO and selected observational studies in which rates of smoking 
were reported in people with psychotic disorders, compared with controls. We calculated the weighted mean diﬀ erence 
for age at onset of psychosis and age at initiation of smoking. For categorical outcomes, we calculated odds ratios 
from cross-sectional studies and risk ratios from prospective studies.
Findings Of 3717 citations retrieved, 61 studies comprising 72 samples met inclusion criteria. The overall sample 
included 14 555 tobacco users and 273 162 non-users. The prevalence of smoking in patients presenting with their ﬁ rst 
episode of psychosis was 0∙57 (95% CI 0∙52–0∙62; p<0∙0001). In case-control studies, the overall odds ratio for the ﬁ rst 
episode of psychosis in smokers versus non-smokers was 3·22 (95% CI 1·63–6·33), with some evidence of publication 
bias (Egger’s test p=0·018, Begg’s test p=0·007). For prospective studies, we calculated an overall relative risk of new 
psychotic disorders in daily smokers versus non-smokers of 2·18 (95% CI 1·23–3·85). Daily smokers developed 
psychotic illness at an earlier age than did non-smokers (weighted mean diﬀ erence –1·04 years, 95% CI –1∙82 to 
–0·26). Those with psychosis started smoking at a non-signiﬁ cantly earlier age than did healthy controls (–0·44 years, 
95% CI –1∙21 to 0∙34).
Interpretation Daily tobacco use is associated with increased risk of psychosis and an earlier age at onset of psychotic 
illness. The possibility of a causal link between tobacco use and psychosis merits further examination.
Funding NIHR Maudsley Biomedical Research Centre.
Copyright © Gurillo et al. Open Access article distributed under the terms of CC BY-NC-ND. 
Introduction
Although the association between smoking tobacco and 
psychosis (in particular, schizophrenia) has been acknow-
ledged,1 the reasons why people with psychosis are more 
likely to smoke compared with the rest of the population 
are still unclear. Several theories have been proposed, 
many focusing on the idea of self-medication—ie, smoking 
corrects a pharmacological abnormality (such as excessive 
dopamine blockade induced by antipsychotics), counteracts 
negative or cognitive symptoms of schizo phrenia,2 or 
relieves boredom or distress. Little attention has been 
directed towards the possibility that cigarette smoking 
might increase risk for the disorder.3 This shortfall is 
surprising, particularly in view of the large amount of 
attention paid to the role of other substances of misuse 
(notably cannabis and stimulants) in the aetiology of 
psychotic illness.4–7 This discrepancy is exempliﬁ ed by two 
meta-analyses: in the ﬁ rst, 83 studies were included in 
which the onset of psychosis and cannabis use was 
analysed;8 in the second, ten studies investigated tobacco 
use and onset of psychotic illness.9
In the second meta-analysis,9 compared with healthy 
controls, an increased risk of tobacco smoking was noted 
in people who developed psychosis (odds ratio 6∙04, 
95% CI 3∙03–12∙02), with no diﬀ erence in age at onset of 
psychosis between smokers and non-smokers (stan dar-
dised mean diﬀ erence –0∙03).10 However, since that 
review was published in 2012, several newer studies have 
become available, with additional data for daily tobacco 
use.11–15 Furthermore, standardised units were used in the 
2012 meta-analysis in place of years for age at onset, 
which was not necessary because all studies used the 
same units (years).
We undertook a systematic review and meta-analysis of 
prospective, case-control, and cross-sectional studies to test 
four hypotheses. First, that an excess of tobacco use is 
already present in people presenting with their ﬁ rst episode 
of psychosis. Second, that daily tobacco use is associated 
with an increased risk of subsequent psychotic disorder. 
Third, that daily tobacco use is associated with an earlier 
age at onset of psychotic illness. Fourth, that an earlier age 
at initiation of smoking is associated with an increased risk 
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of psychotic disorder. We aimed to produce a weighted 
mean diﬀ erence in age at onset, expressed in years. Finally, 
we aimed to estimate the prevalence of smoking in people 
presenting with their ﬁ rst episode of psychosis.
Methods
Systematic review
We did a systematic review in accordance with MOOSE16 
and PRISMA17 guidelines. We searched Embase (from 
1980 to 2014 [week 4]), Medline (1980 to 2014 [week 4]), 
and PsycINFO (from 1980 to 2014 [week 3]) with the 
search terms “schizophrenia” OR “schizo*” OR 
“psychosis” AND “nicotine” OR “smoking” OR “cigarette 
smoking”, with no language restriction. We screened the 
abstracts of articles and retrieved the full text of relevant 
studies; we also checked reference lists and citation 
histories. Two of us (PG and SJ) selected studies.
We included studies that used ICD or DSM criteria 
(from DSM III and ICD-8 onwards) for psychotic 
disorders: schizophrenia, schizophreniform disorder, 
schizoaﬀ ective disorder, delusional disorder, non-
aﬀ ective psychotic disorder, atypical psychosis, psychotic 
depression, and bipolar mania with psychotic features. 
To assess the prevalence of smoking in patients 
presenting with their ﬁ rst episode of psychotic illness, 
we included studies in which the rates of smoking were 
reported for people having contact with secondary 
mental health services for the ﬁ rst time. For our ﬁ rst 
hypothesis, we included studies that also contained a 
control group, so we could calculate odds ratios in 
addition to prevalence. For our second hypothesis, we 
included prospective studies in which rates of smoking 
(daily tobacco use) were reported for patients who 
developed or had psychotic disorders compared with 
controls, enabling calculation of risk ratios. For our third 
and fourth hypotheses, we included prospective and 
case-control studies, and for the onset of psychosis we 
also included cross-sectional studies.
We excluded studies on the basis of insuﬃ  cient data 
or if they met our exclusion criteria. These criteria were 
a primary focus on people with substance-induced 
psychosis, organic psychosis, or learning disability.
Data collection
We extracted data according to a speciﬁ c protocol. First, 
we identiﬁ ed the proportion of smokers and non-
smokers with a diagnosed ﬁ rst episode of psychosis. 
Second, we ascertained the risk of psychosis in daily 
smokers and non-smokers from longitudinal prospective 
studies. Third, we established the mean (with SD) age at 
onset of psychotic illness for daily smokers and non-
smokers. Finally, we looked at initiation of tobacco 
smoking in patients diagnosed with psychotic illness 
versus controls, comparing smokers with non-smokers. 
For every study, we extracted speciﬁ c data to include in 
the model: author, country, and year of publication; type 
of study (ie, prospective, cross-sectional, case-control, 
retro spec tive); demographic characteristics (eg, sex, age); 
clinical assessments (ie, diagnostic criteria, disease 
diagnosed); cannabis and other substances of misuse (ie, 
alcohol, caﬀ eine, cocaine).
Deﬁ nitions
We identiﬁ ed self-reported current tobacco use in the 
included studies. Our preferred term was “daily tobacco 
use”, which we deﬁ ned as either cigarettes smoked per day 
or by use of the term “regular smoking”, or a Fagerström 
Test for Nicotine Dependence score. If the study used 
terms such as “current smoker” or “smoker” without 
stipulating the number of cigarettes or packs smoked per 
day, we did not judge tobacco use to be daily and we did not 
include the study in the analysis of daily smokers.
We deﬁ ned onset of psychotic illness as either ﬁ rst 
psychiatric inpatient care,18–23 start of medical treatment,24 
the ﬁ rst episode of psychosis,19,20,22,23,25–39 or the ﬁ rst 
diagnosis of psychotic illness.18,19,21,24,26–28,30,33,40–46 Because the 
deﬁ nitions of age at onset diﬀ ered, we had to assume that 
the diﬀ erence in age at onset between smokers and non-
smokers was similar, irrespective of the deﬁ nition used.3 
For the same reason, we used a random-eﬀ ects model.
Statistical analysis
We calculated the weighted mean diﬀ erence for con-
tinuous data, which were age at onset of psychosis and 
age at initiation of smoking. For the categorical outcomes 
of rates of tobacco use in patients and controls, we 
Figure 1: Search process
Searched Embase (1980 to week 4, 2014), Medline (1980 to January week 4, 2014),
and PsycINFO (1980 to January week 3, 2014)
3717 records screened by abstract
3581 excluded because no data on age at onset of psychosis, 
           initiation of smoking, or prevalence of smoking and 
           psychotic illness
7 studies added from reference lists
and citation histories
    82 excluded because of insuﬃcient data or other exclusion criteria
61 full-text studies assessed for eligibility, with data reported in cases and controls, 
       and included in the review
72 samples included in review
Data reported in studies
      34 prevalence of tobacco smoking in ﬁrst-episode psychosis
      11 in case-control studies
         5 incidence of psychotic disorder in the general population in longitudinal 
            prospective studies
      23 age at onsent of psychosis
      12 initiation of tobacco smoking 
  136 articles reviewed as full text
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calculated odds ratios from cross-sectional data and 
relative risks from prospective data.
We used Stata version 10 with the metan command. We 
judged a p value less than 0∙05 signiﬁ cant. We used a 
random-eﬀ ects model in all analyses because we expected 
the data to be heterogeneous across studies. We calculated 
I² values to test for heterogeneity between studies. We 
deemed I² less than 25% to have low heterogeneity, 
25–75% to have medium heterogeneity, and greater than 
75% to have high heterogeneity. We also assessed 
publication bias and selective reporting with Egger’s and 
Begg’s tests47,48 and by inspecting the symmetry of funnel 
plots, as recommended in the Cochrane handbook. 
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
report. The corresponding author had full access to all 
data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
61 studies comprising 72 samples were analysed (ﬁ gure 1; 
appendix pp 1–2). 7475 people with psychosis were 
smokers (mean 33·2 per sample [SD 195·7]) and 
5670 people with psychosis were non-smokers (mean 
20·7 per sample [SD 148·1]). Figure 2 shows the 
prevalence of smoking in people presenting with their 
ﬁ rst episode of psychosis. 34 samples were analysed, 
from 34 studies (appendix p 3).11,15,19–23,29,31–33,35–39,46,49–65 In the 
total sample of smokers, prevalence of smoking in people 
presenting with their ﬁ rst episode of psychosis was 
0∙57 (95% CI 0∙52–0∙62; p<0∙0001). Between-sample 
heterogeneity was signiﬁ cant, with an I² of 88·0%.
All deﬁ nitions of smoking (including daily smoking) 
were included in our analysis of smoking prevalence in 
people presenting with their ﬁ rst episode of psychosis. 
12 samples were obtained for the analysis, from 11 case-
control studies.15,21–23,32,34–39 Compared with controls, the 
overall prevalence of smoking in people presenting with 
their ﬁ rst episode of psychosis was three times higher 
(odds ratio 3∙22, 95% CI 1·63–6∙33; p=0∙001; ﬁ gure 3). 
Between-sample heterogeneity was signiﬁ cant, with an 
I² of 82·1%. Findings of Begg’s test (p=0∙007) and Egger’s 
test (p=0∙018) suggested that publication bias might have 
been present. In the analysis of daily smoking status, four 
samples were identiﬁ ed, from three studies,15,21,32 with an 
overall odds ratio of 1∙01 (95% CI 0∙58–1∙76; p=0∙976; 
ﬁ gure 3). Between-sample hetero geneity was signiﬁ cant, 
with an I² of 53·3%.
In our analysis of daily tobacco use and risk of psychotic 
disorder, ﬁ ve longitudinal prospective studies were 
identiﬁ ed of six samples from the general population (all 
samples measured risk of schizophrenia).18–20,46,66 Compared 
with non-smokers, the incidence of new psychotic 
disorders in daily smokers was higher (overall risk ratio 
2∙18, 95% CI 1∙23–3·85; p=0∙007; ﬁ gure 4). Between-
sample heterogeneity was signiﬁ cant, with an I² of 97·7%. 
Some evidence was recorded that publication bias 
contributed to the ﬁ ndings, supported by Egger’s test 
(p=0∙002) and Begg’s test (p=0∙024). We also identiﬁ ed 
one study comprising a cohort of prodromal individuals,33 
in which the risk ratio of developing new-onset psychotic 
illness in daily smokers versus non-smokers was 
7∙00 (95% CI 2∙35–20∙83).
In our analysis of daily tobacco use and age at onset of 
psychosis compared with non-smokers, 26 samples were 
included, from 23 studies.13,19,25–28,30,40–43,46,53,59,61,67–74 Daily 
smokers developed psychotic illness at an earlier age, 
compared with non-smokers (24∙25 years vs 25∙63 years; 
weighted mean diﬀ erence –1∙04, 95% CI –1∙82 to –0∙26; 
p=0∙009; ﬁ gure 5). Between-sample heterogeneity was 
signiﬁ cant, with an I² of 66·3%. No evidence was 
recorded that publication bias contributed to the ﬁ ndings, 
For the Cochrane handbook see 
http://handbook.cochrane.org
See Online for appendix
Figure 2: Prevalence of smoking in individuals presenting with their ﬁ rst episode of psychosis
Black diamonds represent prevalences; grey squares represent weights; horizontal lines represent 
95% CIs; white diamonds represent subtotal or overall prevalence (dotted line) and 95% CIs. 
*From random-eﬀ ects analysis.
Prevalence (95% CI) Weight (%)*
Non-daily smokers
Baeza (2009)
Strassnig (2007)
Reddy (2003)
Kopala (1992)
Reddy (2004)
Smesny (2007)
Pérez−Iglesias (2009)
Smith (2010)
Smesny (2005)
Harrison (2008)
Curtis (2011)
Berk (2010)
McCreadie (2000)
McEvoy (1999)
Sengupta (2008)
Subtotal 
Daily smokers
Zhang (2013)
deRuiter (2013)
Hakko (2006)
Compton (2009)
Weiser (2004)
Riala (2005)
Ilomäki (2008)
Samele (2007)
Zabala (2009)
Luty (2002)
Smith (2009)
Zammit (2003)
Kotov (2010)
Hides (2009)
Kristensen (2007)
Barrigon (2010)
Brewer (2001)
Wade (2005)
Hilti (2010)
Subtotal
Overall
0·31 (0·22–0·40)
0·34 (0·24–0·43)
0·42 (0·25–0·59)
0·43 (0·27–0·58)
0·46 (0·26–0·66)
0·47 (0·25–0·70)
0·59 (0·52–0·67)
0·60 (0·53–0·68)
0·63 (0·46–0·81)
0·64 (0·54–0·75)
0·66 (0·56–0·76)
0·72 (0·66–0·78)
0·73 (0·58–0·89)
0·77 (0·60–0·95)
0·79 (0·66–0·92)
0·57 (0·49–0·66)
0·36 (0·30–0·42)
0·43 (0·35–0·51)
0·44 (0·28–0·59)
0·44 (0·35–0·53)
0·45 (0·31–0·60)
0·46 (0·37–0·56)
0·48 (0·36–0·59)
0·49 (0·39–0·60)
0·51 (0·38–0·63)
0·52 (0·31–0·74)
0·54 (0·44–0·63)
0·61 (0·55–0·66)
0·66 (0·60–0·71)
0·66 (0·60–0·72)
0·67 (0·29–1·04)
0·71 (0·63–0·80)
0·73 (0·59–0·86)
0·77 (0·70–0·84)
0·83 (0·69–0·97)
0·56 (0·50–0·63)
0·57 (0·52–0·62)
 3·27
 3·22
 2·50
 2·69
 2·27
 2·06
 3·36
 3·36
 2·51
 3·13
 3·16
 3·43
 2·64
 2·49
 2·90
 42·99
 3·45
 3·33
 2·66
 3·22
 2·74
 3·21
 3·04
 3·13
 2·94
 2·15
 3·23
 3·50
 3·49
 3·43
 1·15
 3·29
 2·82
 3·37
 2·83
 57·01
 100·00
Prevalence increased
0 1·00
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as shown by Egger’s test (p=0∙149) and Begg’s test 
(p=0∙103). When the analysis was divided according to 
the study country,75 a signiﬁ cant diﬀ erence was noted 
between group means (one-way ANOVA F=4∙32; 
p=0∙049). Our analysis was based on data showing 
diﬀ erences in the age at initiation of smoking in 
countries in Europe, North America, and Australasia (eg, 
Australia, Finland, Spain, Sweden, and the USA) versus 
countries in Asia and the Middle East (eg, Egypt, Japan, 
and Turkey); speciﬁ cally, women in Asian countries were 
seen to begin smoking at a later age. In Europe, North 
America, and Australasia, 18 samples from 16 studies 
were analysed,13,19,25,26,28,40–43,46,53,59,61,67,68,70 with a weighted 
mean diﬀ erence of –1∙56 (95% CI –2·52 to –0∙59; 
p=0∙002; ﬁ gure 5). In Asia and the Middle East, eight 
samples from seven studies were analysed,27,30,69,71–74 with a 
weighted mean diﬀ erence of 0∙24 (–0∙56 to 1∙04; 
p=0∙554). No between-sample heterogeneity was 
recorded, with an I² of 0%.
In the analysis of age at initiation of smoking in people 
with psychosis compared with controls, 15 samples were 
identiﬁ ed from 12 studies.12,14,19,24,26,31,32,43–45,53,76 Age at initiation 
of smoking cigarettes did not diﬀ er between patients with 
psychosis and controls, with a weighted mean diﬀ erence 
of –0·44 (95% CI –1·21 to 0∙34; p=0∙270; ﬁ gure 6). 
Between-sample hetero geneity was signiﬁ cant, with an 
I² of 81·0%. No evidence was recorded that publication 
bias contributed to the ﬁ ndings, supported by Egger’s test 
(p=0∙957) and Begg’s test (p>0∙99).
Discussion
The ﬁ ndings of our systematic review and meta-analysis 
show that daily tobacco use is associated with an 
increased risk of psychotic disorder and an earlier age at 
onset of psychotic illness. However, the eﬀ ect of smoking 
seems to be modest.
The prevalence of smoking in patients presenting with 
their ﬁ rst episode pf psychosis was 57% (95% CI 52–62). 
From our analysis of case-control studies, the overall risk 
of smoking in individuals having their ﬁ rst episode of 
psychosis was three times higher than that for non-
smokers, with a suggestion of possible publication bias. 
However, when we restricted the analysis to three studies 
in which daily cigarette smoking was speciﬁ ed, the 
association disappeared. Our ﬁ ndings diﬀ er from those 
of a previous meta-analysis,9 in which risk of smoking in 
ﬁ rst-episode psychosis was much higher, but a diﬀ erent 
set of studies were included in that meta-analysis. Our 
analysis consisted of studies published up to 2014, and 
we included two cohorts from China,15 a country with a 
lower prevalence of smoking than Europe and North 
America. To acknowledge diﬀ erences between countries, 
we analysed cohorts from the general population around 
the world (appendix p 3).77 Few studies reported daily 
smoking status.
Analysis of ﬁ ve longitudinal prospective studies18–20,46,66 
showed that the risk of psychotic disorder was increased 
modestly by daily smoking. In two other studies that did 
not meet our inclusion criteria—one of prodromal 
psychosis33 and another looking at the risk of developing 
non-aﬀ ective psychosis in individuals who had been 
smoking for at least 9 years78—the risk was much higher.
In our analysis, daily use of tobacco was associated 
with an earlier onset of psychosis compared with non-
smokers. These ﬁ ndings conﬂ ict with previous 
reports,7,10 in which no relation was noted between 
smoking status and age at onset of psychosis. This 
discrepancy could be accounted for by diﬀ erences in 
culture—eg, in countries such as the USA and the UK, 
both boys and girls initiate smoking at an earlier age 
(around 17 years old),28,32,43 whereas in countries such as 
Egypt and Turkey, boys start to smoke earlier than do 
girls.79 In a Chinese study,80 the mean age at onset of 
regular smoking in a cohort with schizophrenia was 
20∙8 years. Possible reasons for taking up smoking 
early could be related to self-medication for symptoms 
Figure 3: Odds ratio of smoking daily and non-daily, in people with ﬁ rst-episode psychosis versus controls
Black diamonds represent odds ratios; grey squares represent weights; horizontal lines represent 95% CIs; white 
diamonds represent subtotal or overall odds ratios (dotted line) and 95% CIs. *From random-eﬀ ects analysis.
Daily smokers
Luty (2002)
Zhang (2013), women
Zhang (2013), men
Samele (2007)
Subtotal
Non-daily smokers
Smesny (2007)
Cadenhead (2011)
Strassnig (2007)
Smesny (2005)
Kopala (1992)
Reddy (2004)
Reddy (2003)
Sengupta (2008)
Subtotal
Overall
 0·52 (0·16–1·72)
 0·82 (0·24–2·81)
 0·83 (0·54–1·28)
 1·92 (1·05–3·52)
 1·01 (0·58–1·76)
 1·54 (0·42–5·64)
 2·86 (1·31–6·24)
 4·57 (1·29–16·18)
 6·22 (1·80–21·45)
 6·41 (2·24–18·35)
 13·12 (2·54–67·61)
 27·44 (3·33–226·33)
 30·00 (8·18– 110·02)
 6·41 (3·24–12·66)
 3·22 (1·63–6·33)
 8·27
 8·16
 10·69
 10·25
 37·37
 7·92
 9·72
 8·04
 8·13
 8·79
 6·75
 5·36
 7·91
 62·63
 100·00
10·00442 226
Weight (%)*Odds ratio (95% CI)
Greater odds of 
smoking in controls
Greater odds of
smoking in cases
Figure 4: Risk of psychosis in prospective studies in daily smokers versus non-smokers
Black diamonds represent relative risks; grey squares represent weights; horizontal lines represent 95% CIs; white 
diamond represents overall relative risk (dotted line) and 95% CI. *From random-eﬀ ects analysis.
Zammit (2003)
Sørensen (2011)
Riala (2005)
Weiser (2004)
Kendler (2015), women (1–9 cigarettes per day)
Kendler (2015), women (≥10 cigarettes per day)
Overall
1·08 (0·88–1·34)
1·37 (1·10–1·72)
2·06 (1·41–3·01)
2·10 (1·16–3·79)
2·94 (2·57–3·37)
5·50 (4·79–6·31)
2·18 (1·23–3·85)
 17·13
 17·09
 16·29
 14·76
 17·37
 17·37
 100·00
10·159 6·31
Lower risk
in smokers
Higher risk
in smokers
Relative risk
(95% CI)
Weight
(%)*
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of anxiety or isolated psychosis and might be shared 
with other risk factors for psychosis, such as early life 
stressors or living in an urban setting. Therefore, for 
individuals at increased risk, smoking could have an 
additive eﬀ ect.
In our analysis, people with psychosis began smoking 
0∙44 years earlier than did controls, although this 
diﬀ erence was not signiﬁ cant. Findings of another meta-
analysis estimated a pooled interval of 5∙8 years between 
age at initiation of daily tobacco use and onset of psychosis.9 
In another study, children who started smoking at 15 years 
or younger were more likely to develop non-aﬀ ective 
psychosis than were individuals smoking at a later age.78
In view of all our ﬁ ndings, we think that the earlier 
onset of psychosis and higher risk in smokers of 
developing psychosis (albeit based on few studies) calls 
into question the self-medication hypothesis. The excess 
of smoking nicotine by people with psychosis has been 
assumed to be secondary to several factors associated 
with psychosis, subsumed under the umbrella term self-
medication. Nicotine use has been suggested to reduce 
cognitive deﬁ cits and symptoms (such as visuospatial 
working memory and attention deﬁ cits,81 working 
memory, and selective attention),82 P50 inhibition,83 
sensory gating, smooth pursuit, and antisaccadic eye 
movements.84 Nicotine has also been postulated to 
reduce sedating and other eﬀ ects of antipsychotic drugs28 
and to diminish negative symptoms of psychosis. Use of 
nicotine at a young age could be attributed to self-
medication for anxiety in individuals at the prodromal 
stage of illness. However, a 2008 review stated that the 
tobacco industry monitored or directly funded research 
promoting the self-medication hypothesis, in particular, 
biological research.85 Furthermore, direct behavioural 
evidence has failed to show attentional beneﬁ ts with 
nicotine by comparison with placebo, in smokers with 
schizophrenia versus controls.86
With the Bradford Hill criteria, which consider the 
strength, consistency, speciﬁ city, temporality, biological 
gradient, plausibility, coherence, experiment, and 
analogy of an association,87 we propose that smoking 
could have a causal role in psychosis. First, with respect 
to strength, the association noted in prospective studies 
undertaken in the general population shows a modest 
increase in relative risk. Second, the ﬁ ndings seem to be 
consistent between diﬀ erent populations.7,10 Third, with 
respect to temporality, although people with psychosis do 
not smoke at an earlier age compared with the general 
population, evidence suggests that an excess of smoking 
precedes the onset of psychotic illness.9 Fourth, daily 
smoking seems to have a greater eﬀ ect on positive 
symptoms of psychosis.88 Fifth, plausible mechanisms 
have been proposed between nicotine and the dopamine 
system, which have been corroborated in epidemiological 
and laboratory studies.  Finally, the eﬀ ects of nicotine 
exposure on the dopamine system might have similarities 
to psychosis.70,89,90 The speciﬁ city criterion cannot be 
applied to smoking, because smoking aﬀ ects a substantial 
number of disease processes. Also, the experiment 
criterion is not met because models of important aspects 
of psychotic illness in animals such as delusions and 
hallucinations are impossible to achieve.
In implicating nicotine to have a causal role in psychosis 
(the plausibility part of the Bradford Hill criteria), we 
must consider whether nicotine has an eﬀ ect on the 
dopamine system, since the hypothesis of excess striatal 
dopamine is the leading pathogenic theory of schizo-
phrenia.91 One of the strongest links between the 
environment and Parkinson’s disease (a dopamine 
deﬁ ciency disorder, in some ways the opposite of 
schizophrenia) is the inverse relation between nicotine 
and risk of Parkinson’s disease.90 In vivo, nicotine might 
increase dopamine release directly (measured by PET in 
the dorsal–ventral striatum and basal ganglia) to a similar 
degree as other drugs of misuse.70,91 Another mechanism 
by which nicotine could cause a change in the dopamine 
system could be through in duction of supersensitivity of 
D2 receptors, which has been proposed as an explanatory 
Figure 5: Diﬀ erence in age at onset of psychosis, in countries around the world, for daily smokers versus 
non-daily smokers
Black diamonds represent weighted mean diﬀ erences; grey squares represent weights; horizontal lines represent 
95% CIs; white diamonds represent subtotal or overall weighted mean diﬀ erences (dotted line) and 95% CIs. 
OCS=obsessive-compulsive symptoms. *From random-eﬀ ects analysis.
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